SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| EVISTA 60 MG F-C TABLETS | 60 mg | Film-coated tablet · Oral use | 28 Blister | SAR 88.55 | NCE · Prescription | Eli Lilly Nederland B.V | Valid |
| RALOSTA 60MG | 60 mg | Film-coated tablet · Oral use | 28 Blister | SAR 104.70 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BURKITT`S LYMPHOMA; CASTLEMAN DISEASE; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; OSTEOPOROSIS
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
Evista Substipharm · Authorised · authorised 5 Aug 1998 · ATC G03XC01
Therapeutic indication (EMA)
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Optruma Eli Lilly Nederland B.V. · Authorised · authorised 5 Aug 1998 · ATC G03XC01
Therapeutic indication (EMA)
Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).
Raloxifene Teva Teva B.V. · Authorised · authorised 29 Apr 2010 · ATC G03XC01
Therapeutic indication (EMA)
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | EVISTA 60 MG TABLET | $6.34306 | per EA | 23 Sep 2026 |
| US NADAC | RALOXIFENE HCL 60 MG TABLET | $0.22348 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Raloxifene 60mg tablets | £5.08 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.